Xiang Xie, MD, PhD. EDUCATION/TRAINING Bachelor Degree in Medicine (Clinical Medicine), 09/95-07/98 Linyi Medical College, Liyi, China   Master’s Degree in Medicine, (Internal Medicine), 09/06-07/09 Doctor’s Degree in Medicine, (Internal medicine), 09/09-07/12 Xinjiang Medical University, Urumqi, Xinjiang, China   Research Fellow, 01/14-03/14 Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.   Research Fellow, 10/15-present National Heart Centre, Singapore   PROFESSIONAL EXPERIENCES Resident, 07/98-11/05 Attending physician, 12/05-08/06 Department of Internal Medicine, Caoxian Prefecture Hospital, Caoxian, China.   Attending physician/Lecturer, 09/09-11/11 Associate chief physician/Lecturer, 12/11-11/12 Associate chief physician/Associate Professor, 12/12-12/17 Chief physician/ Professor, 12/17-Present Department of Cardiology, First affiliated Hospital of Xinjiang Medical University Urumqi, Xinjiang, China Major Professional/Academic Contributions: As the main investigator, we built up more systematic and comprehensive epidemiological data for the cardiovascular disease in Xinjiang different ethnics, and found new trends and risk factors of cardiovascular disease in Xinjiang (JAHA. 2017, Scientific Rep. 2017, PLoS One. 2010；Eur J Prev Cardiol. 2012；Blood Press. 2013). As the first contributor, we carried out comprehensive molecular genetic studies on atherosclerosis and coronary heart disease (CHD) in different nationalities in Xinjiang, and found several susceptibility genes of CHD. We identified six new loci relevant to the susceptibility of CHD in different nationalities. (Tissue Antigens. 2015; PLoS One. 2012；PLoS One. 2010；Clin Chem Lab Med. 2011；Clin Chem Lab Med. 2009；Blood Press. 2011). As the first contributor, we designed a randomized controlled trial (RCT) and a cohort study, respectively, to describe the effect of detection of CYP2C19 phenotypes on the personalized antiplatelet therapy in CHD patients, and established novel mode of personalized therapy for CHD based on the genetic background of the patients. The research received the Best Clinical Research Award from the Cardiovascular Branch of Chinese Medical Association in 2013 (Int J Cardiol. 2013; PLoS One. 2013).   Professional Membership: 1. American College of Cardiology, Fellow, (FACC), 2017-present 2. Chinese Society of Cardiology (CSC), Fellow 2013-present 3. Chinese Medical Doctor Association, Member 2014-present 4. Heart Disease Prevention and Control Committee, Chinese Preventive Medicine Association, Member 2015-present 5. Precision Cardiovascular Branch, China Health Care International Exchange Promotion Association, Member, 2016-present 6. Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association, Member, 2017-present   Awards & Honors: Scientific and technological progress award The Government of Xinjiang Uygur Autonomous Region, China (2012, 2013, 2015, 2018) Advanced worker, First affiliated Hospital of Xinjiang Medical University, China (2010) Science Paper Award, The Government of Xinjiang Uygur Autonomous Region, China (2010, 2012). Best Clinical Research Award, Cardiovascular Branch of the Chinese Medical Association (2013)   Grants: Principal Investigator Title: The Pathogenic Mechanism of a New Variant of CYP17A1 Gene in a Premature Coronary Heart Disease Family. Fund: The National Natural Science Foundation of China (NSFC), Beijing, China. Project No. 81770235 Duration: 01/18-12/21   Principal Investigator Title: Identification and Functional Study of Pathogenesis-related Genes in Ischemic Stroke Family Lines. Fund: The National Natural Science Foundation of China (NSFC), Beijing, China. Project No. U1603381 Duration: 01/17-12/20   Principal Investigator Title: The Role and Molecular Mechanism of Sels Gene in Heterogeneity of Coronary Heart Disease in Different Ethnic Groups in Xinjiang Fund: The National Natural Science Foundation of China (NSFC), Beijing, China. Project No. 81560070 Duration: 01/16-12/19   Principal Investigator Title: Efffect and mechanism of SAA gene on the coronary heart disease heterogeneity between different ethnic groups in Xinjiang. Fund: The National Natural Science Foundation of China (NSFC), Beijing, China. Project No. 81160017 Duration: 01/12-12/15   Principal Investigator Title: Identification and functional study of pathogenic gene in Uygur early-onset coronary heart disease-related genes in pedigree. Fund: NSFC, Beijing, China. Project No. 81470014 Duration: 01/15-12/16   Principal Investigator Title: Effect of Tanis gene in the pathogenesis of coronary heart disease. Fund: China Postdoctoral Science Foundation, Beijing, China, Project 2014T70956 Duration: 01/14-12/15     Major Academic Contributions: As the principal investigator, we establised large sample size cohort of coronary heart disease, found many novel predictors of outcomes of patients who underwent PCI, and developed several new diagnostic predictive models of coronary heart disease.( Nat Rev Cardiol. 2020 ; Thromb Haemost. 2020; J Agric Food Chem. 2020; Catheter Cardiovasc Interv. 2020; Eur Heart J Cardiovasc Pharmacother. 2020; Eur J Prev Cardiol. 2020) As the main investigator, we established more systematic and comprehensive epidemiological data of Xinjiang different ethnics in cardiovascular disease. Based on these data, we found new trends and risk factors of cardiovascular disease in Xinjiang (PLoS One. 2010；Eur J Prev Cardiol. 2012；Blood Press. 2013). As the first contributor, we carried out comprehensive molecular genetic studies on atherosclerosis and coronary heart disease (CHD) in different nationalities in Xinjiang. We found several susceptibility genes of CHD. We identified six new loci contributed to coronary heart disease susceptibility in different nationalities. Therefore, we achieved a major breakthrough and innovation in the mechanisms of coronary heart disease susceptibility research (Tissue Antigens. 2015; PLoS One. 2012；PLoS One. 2010；Clin Chem Lab Med. 2011；Clin Chem Lab Med. 2009；Blood Press. 2011). As the first contributor, we designed a randomized controlled trial (RCT) and a cohort study, respectively, to describe the effect of detection of CYP2C19 phenotypes on the personalized antiplatelet therapy in CHD patients, and established novel mode of personalized therapy for CHD according to the patients genetic background. Our research gained the"Best Clinical Research Award" from the Cardiovascular Branch of Chinese Medical Association in 2013 (Int J Cardiol. 2013; PLoS One. 2013 ).   PUBLICATIONS   Ying-Ying Zheng , Yi-Tong Ma, Jin-Ying Zhang , Xiang Xie. COVID-19 and the Cardiovascular System. Nat Rev Cardiol. 2020;17(5):259-260. Ying-Ying Zheng, Yi-Tong Ma, Jin-Ying Zhang, Xiang Xie. Reply To: 'Interaction Between RAAS Inhibitors and ACE2 in the Context of COVID-19'. Nat Rev Cardiol. 2020;17(5):313-314. Zheng YY, Wu TT, Yang Y, Hou XG, Gao Y, Chen Y, Yang YN, Li XM, Ma X, Ma YT, Xie X. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211-221. Zheng YY, Wu TT, Liu ZQ, Li A, Guo QQ, Ma YY, Zhang ZL, Xun YL, Zhang JC, Wang WR, Kadir P, Wang DY, Ma YT, Zhang JY, Xie X. Gut Microbiome-Based Diagnostic Model to Predict Coronary Artery Disease. J Agric Food Chem. 2020 Mar 18;68(11):3548-3557. Zheng YY, Wu TT, Chen Y, Hou XG, Yang Y, Zhang JY, Ma YT, Xie X. Platelet-to-hemoglobin ratio as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: A retrospective cohort study. Eur J Prev Cardiol. 2019 Oct 4:2047487319870346. doi: 10.1177/2047487319870346. Zheng YY; Wu TT; Chen Y; Hou XG; Yang Y; Ma X; Ma YT; Zhang JY; Xie X. percutaneous coronary intervention: a retrospective cohort study, Thrombosis and Haemostasis, 2019.3.1, 119(3) Zheng YY, Wu TT, Gao Y, Guo QQ, Ma YY, Zhang JC, Xun YL, Wang DY, Pan Y, Cheng MD, Song FH, Liu ZY, Wang K, Jiang LZ, Fan L, Yue XT, Bai Y, Zhang ZL, Dai XY, Zheng RJ, Chen Y, Ma X, Ma YT, Zhang JY, Xie X. A Novel ABC Score Predicts Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Who underwent Percutaneous Coronary Intervention. Thromb Haemost. 2020 Oct 31. doi: 10.1055/s-0040-1718411. Wu TT, Chen Y, Zhou Y, Adi D, Zheng YY, Liu F, Ma YT, Xie X. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 May 5;6(5). pii: e004896. doi: 10.1161/JAHA.116.004896. Zhang JZ, Kang XJ, Gao Y, Zheng YY, Wu TT, Li L, Liu F, Yang YN, Li XM, Ma YT, Xie X. Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis. Sci Rep. 2017 Apr 21;7(1):1045. Zhang JZ, Gao Y, Zheng YY, Liu F, Yang YN, Li XM, Ma X, Ma YT, Xie X. Increased serum resistin level is associated with coronary heart disease. Oncotarget. 2017 Jul 25;8(30):50148-50154. Zhang MM, Gao Y, Zheng YY, Chen Y, Liu F, Ma YT, Xie X. Association of Fasting Serum Bilirubin Levels with Clinical Outcomes After Percutaneous Coronary Intervention: A Prospective Study. Cardiovasc Toxicol. 2017 Mar 10. doi: 10.1007/s12012-017-9405-3. Zheng YY, Xie X, Ma YT, Fu ZY, Ma X, Yang YN, Li XM, Pan S, Adi D, Chen BD, Liu F. Association of C5L2 genetic polymorphisms with coronary artery disease in a Han population in Xinjiang, China. Oncotarget. 2017 Jan 31;8(5):8590-8596. Zhang MM, Zheng YY, Gao Y, Zhang JZ, Liu F, Yang YN, Li XM, Ma YT, Xie X. Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis. Oncotarget. 2016;7(50):83437-83450. Xie X, Zheng YY, Adi D, Yang YN, Ma YT, Li XM, Fu ZY, Ma X, Liu F, Yu ZX, Chen Y, Huang Y. Exome Sequencing in a Family Identifies RECQL5 Mutation Resulting in Early Myocardial Infarction. Medicine (Baltimore). 2016;95(5):e2737. Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Ma X, Fu ZY, Ba Bayinsilema, Li Y, Yu ZX, Chen Y, Chen BD, Liu F, Huang Y, Liu C, Baituola G. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168(4):3736-40. Zhang JZ, Xie X*, Ma YT, Zheng YY, Yang YN, Li XM, Fu ZY, Dai CF, Zhang MM, Yin GT, Liu F, Chen BD, Gai MT. Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis. Aging Dis. 2016;7(1):36-44. Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Liu F, Ma X, Fu ZY, Yu ZX, Chen Y, Chen BD, Huang Y. Genetic polymorphisms of serum amyloid A1 and coronary artery disease risk. Tissue Antigens. 2015;85(3):168-76.. Xie X, Ma YT, Yang YN, Li XM, Ma X, Fu ZY, Zheng YY, Chen BD, Liu F. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One. 2013;8(3):e59344.. Xie X, Ma YT, Yang YN, Li XM, Fu ZY, Zheng YY, Ma X, Chen BD, Liu F, Huang Y, Yu ZX, Chen Y. Serum uric acid levels are associated with polymorphism in the SAA1 gene in Chinese subjects. PLoS One. 2012;7(6):e40263. Xie X, Ma YT, Yang YN, Li XM, Liu F, Huang D, Fu ZY, Ma X, Chen BD, Huang Y. Alcohol consumption and ankle-to-brachial index: results from the Cardiovascular Risk Survey. PLoS One. 2010;5(12):e15181. Xie X, Ma YT, Yang YN, Fu ZY, Ma X, Huang D, Li XM, Chen BD, Liu F, Huang Y, Liu C, Zhang XL, Zheng YY, Baituola G, Wang BZ, Du L, Gao X. Alcohol consumption and carotid atherosclerosis in China: the Cardiovascular Risk Survey. Eur J Prev Cardiol. 2012 Jun;19(3):314-21. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Huang D, Ma X, Chen BD, Liu F. Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One. 2010;5(11):e13997. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Huang D, Ma X, Chen BD, Liu F. Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population. Clin Chem Lab Med. 2011;49(1):55-60. Xie X, Ma YT, Fu ZY, Yang YN, Ma X, Chen BD, Wang YH, Liu F. Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin Chem Lab Med. 2009;47(3):347-52. Xie X, Ma YT, Yang YN, Li XM, Fu ZY, Ma X, Chen BD, Liu F, Huang Y, Zheng YY, Yu ZX, Chen Y, Huang D. Decreased estimated glomerular filtration rate (eGFR) is not an independent risk factor of arterial stiffness in Chinese women. Blood Press. 2013;22(2):73-9. Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Zheng YY, Huang D, Ma X, Chen BD, Liu F. Polymorphisms in the SAA1 gene are associated with ankle-to-brachial index in Han Chinese healthy subjects. Blood Press. 2011;20(4):232-8. Xiang Xie, Ma YT, Fu ZY, Yang YN, Xiang Ma, Chen BD, Wang YH, Fen Liu. Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb Hemost. 2009;15(5):574-80. Chuan-Fang Dai, Xiang Xie*, Yi-Tong Ma, Yi-Ning Yang, Xiao-Mei Li, Zhen-Yan Fu, Fen Liu, Bang-Dang Chen, Min-Tao Gai. Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population. Aging and Disease.;6(6):486-98. Dai CF, Xie X*, Ma YT, Yang YN, Li XM, Fu ZY, Liu F, Chen BD, Gai MT.The relationship between the polymorphisms of the CYP17A1 gene and hypertension: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1314-20. Yin GT, Ma YT, Zheng YY, Yang YN, Li XM, Fu ZY, Zhang JZ, Dai CF, Liu F, Chen BD, Gai MT, Xie X*. Polymorphisms of interleukin-10 genes on the risk of ischemic stroke in a meta-analysis. Int J Clin Exp Med. 2015;8(2):1888-95. Dai CF, Xie X, Yang YN, Li XM, Zheng YY, Fu ZY, Liu F, Chen BD, Gai MT, Ma YT. Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population. Lipids Health Dis. 2015;14(1):16. Dai CF, Xie X*, Ma YT, Yang YN, Li XM, Fu ZY, Liu F, Chen BD, Gai MT. Haplotype analyses of CYP17A1 genetic polymorphisms and coronary artery disease in a Uygur population. J Renin Angiotensin Aldosterone Syst. 2015;16(2):389-98. Gao Y, Xie X, Cianflone K, Lapointe M, Guan J, Bu-Jiaer GW, Chen D, Zhao WY, Ma YT. Ethnic differences in acylation stimulating protein (ASP) in Xinjiang Uygur autonomous region, China. Int J Clin Exp Med. 2015; 8(2):2823-30 Zheng YY, Xie X, Ma YT, Fu ZY, Ma X, Yang YN, Li XM, Pan S, Adi D, Chen BD, Liu F. Association of C5L2 genetic polymorphisms with coronary artery disease in a Han population in Xinjiang, China. Oncotarget. 2017;8(5):8590-8596. Adi D, Xie X, Xiang Y, Ma YT, Yang YN, Fu ZY, Li XM, Liu F, Chen BD. Polymorphisms of COL4A1 gene are associated with arterial pulse wave velocity in healthy Han Chinese and Uygur subjects. Int J Clin Exp Med. 2015;8(2):2693-701. Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Pan S, Adi D, Chen BD, Liu F. Association of C5aR1genetic polymorphisms with coronary artery disease in a Han population in Xinjiang, China. Diagn Pathol. 2015;10(1):33. Yuan Q, Xie X, Fu Z, Ma X, Yang Y, Huang D, Liu F, Dai C, Ma Y. Association of the histone-lysine N-methyltransferase MLL5 gene with coronary artery disease in Chinese Han people. Meta Gene. 2014;2:514-24. Huang D, Xie X, Ma YT, Huang Y, Ma X. Endothelial lipase-384A/C polymorphism is associated with acute coronary syndrome and lipid status in elderly Uygur patients in Xinjiang.Genet Test Mol Biomarkers. 2014;18(11):781-4. Zou JG, Ma YT, Xie X, Yang YN, Pan S, Adi D, Liu F, Chen BD. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China.Lipids Health Dis. 2014;13:145. Luo JY, Ma YT, Xie X, Yang YN, Li XM, Ma X, Yu Z, Chen BD, Liu F. Association of intercellular adhesion molecule‑1 gene polymorphism with coronary heart disease. Mol Med Rep. 2014;10(3):1343-8. Li X, Ma YT, Xie X, Yang YN, Ma X, Zheng YY, Pan S, Liu F, Chen BD. Association of Egr3 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. Lipids Health Dis. 2014;13:84. Adi D, Xie X, Ma YT, Fu ZY, Yang YN, Li XM, Xiang Y, Liu F, Chen BD. Association of COL4A1 genetic polymorphisms with coronary artery disease in Uygur population in Xinjiang, China. Lipids Health Dis. 2013;12:153. Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F. A novel polymorphism (901G > a) of C5L2 gene is associated with coronary artery disease in Chinese Han and Uyghur population. Lipids Health Dis. 2013;12:139. Gao Y, Xie X, Ma YT, Yang YN, Li XM, Fu ZY, Zheng YY, Ma X, Chen BD, Liu F, Huang Y. Genetic variation in Tanis was associated with elevating plasma triglyceride level in Chinese nondiabetic subjects. Lipids Health Dis. 2013;12:97. Yang YN, Xie X, Ma YT, Li XM, Fu ZY, Ma X, Huang D, Chen BD, Liu F, Huang Y, Liu C, Zheng YY, Baituola G, Yu ZX, Chen Y. Type 2 diabetes in Xinjiang Uygur autonomous region, China. PLoS One. 2012;7(4):e35270. Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F. Epub 2011 Relationship between type 2 diabetes mellitus and a novel polymorphism C698T in C5L2 in the Chinese Han population. Endocrine. 2012;41(2):296-301. Zheng YY, Xie X, Ma YT, Yang YN, Fu ZY, Li XM, Ma X, Chen BD, Liu F. Relationship between a novel polymorphism of the C5L2 gene and coronary artery disease. PLoS One. 2011;6(6):e20984.